Repare Therapeutics (RPTX) AI Stock Analysis

• Market Cap: $76.47M
• Dividend Yield: N/A
• Average Volume (3M): 138.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: -82.16%
• EPS Growth: 14.58%
• Country: US
• Employees: 129
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.08
• Shares Outstanding: 42,959,170
• 10 Day Avg. Volume: 221,679
• 30 Day Avg. Volume: 138,921
• PEG Ratio: 0.06
• Price to Book (P/B): 0.37
• Price to Sales (P/S): 1.04
• P/FCF Ratio: -0.73
• Enterprise Value/Market Cap: -0.64
• Enterprise Value/Revenue: -4.14
• Enterprise Value/Gross Profit: -4.81
• Enterprise Value/Ebitda: 0.68
• 1Y Price Target: $3.00
• Price Target Upside: 41.51% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $2.00 ▼(-5.66% Downside)

Repare Therapeutics' stock score is primarily influenced by its financial performance and technical analysis. The company faces significant financial challenges, but its strong cash position provides some stability. Technical indicators show positive momentum, though the stock is currently overbought. Valuation remains a concern due to negative earnings and lack of dividends.

Positive Factors

Strong Cash Position

A strong cash position provides Repare Therapeutics with the liquidity needed to sustain operations and invest in R&D, crucial for a biotech firm focused on drug development.

Low Debt-to-Equity Ratio

A low Debt-to-Equity ratio suggests financial stability, allowing Repare Therapeutics to focus on long-term growth without the pressure of high debt obligations.

Innovative Product Pipeline

Repare's focus on precision medicine and its innovative pipeline positions it well in the oncology sector, potentially leading to breakthroughs in cancer treatment.

Negative Factors

Revenue Volatility

Significant revenue volatility indicates challenges in achieving consistent financial performance, which can hinder long-term planning and investment.

Consistent Operating Losses

Ongoing operating losses reflect operational inefficiencies and challenge Repare's ability to achieve profitability, impacting its financial health.

Negative Free Cash Flow

Negative free cash flow suggests that Repare is not generating sufficient cash from operations, which may limit its ability to fund new projects or expand its pipeline.

Repare Therapeutics Business Overview & Revenue Model

Company Description

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

How the Company Makes Money

Repare Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies that are interested in co-developing its drug candidates. The company may receive upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales of any products that result from these partnerships. Additionally, Repare may engage in strategic licensing agreements, allowing other firms to develop or commercialize its technologies, further contributing to its revenue streams. Research grants and funding from government or non-profit organizations aimed at supporting cancer research may also play a role in its financial model.

Repare Therapeutics Financial Statement Overview

Summary

Repare Therapeutics faces significant financial challenges with consistent losses and revenue volatility. Despite these issues, the balance sheet shows relative stability with a strong cash position and low leverage, providing some buffer for future operations.

Income Statement

Repare Therapeutics has shown significant revenue volatility over the years, with revenue dropping to zero in the most recent period from $51.13 million the previous year and $131.83 million two years prior. The company has consistently incurred operating losses, and negative net income, indicating ongoing profitability challenges. The EBIT and EBITDA margins are negative, reflecting operational inefficiencies. However, the company showed a brief revenue surge in 2022, which might indicate potential for recovery.

Balance Sheet

The company maintains a strong equity base relative to its liabilities, reflected in a low Debt-to-Equity ratio, which suggests stability. Despite consistent net losses, Repare's cash position remains robust, indicating prudent cash management. However, the Return on Equity is negative due to sustained net losses, which impacts overall shareholder returns negatively. The equity ratio has shown some decline but remains relatively healthy.

Cash Flow

Repare Therapeutics has faced challenges with negative free cash flow, although the cash flow from investing activities has been positive, largely due to asset management. The operating cash flow remains negative, indicating that the company is not generating enough cash from core operations to cover expenses. However, the company has managed to sustain cash reserves, which provides liquidity to continue operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.87M	53.48M	51.13M	131.83M	7.60M	135.00K
Gross Profit	10.23M	40.10M	37.89M	15.11M	-80.25M	-38.64M
EBITDA	-71.98M	-90.22M	-114.27M	-17.82M	-107.19M	-53.41M
Net Income	-72.20M	-84.69M	-93.80M	-29.05M	-106.91M	-53.42M
Balance Sheet
Total Assets	126.75M	176.51M	253.90M	364.07M	368.71M	357.09M
Cash, Cash Equivalents and Short-Term Investments	112.60M	152.79M	223.63M	343.94M	341.87M	333.71M
Total Debt	342.00K	1.93M	3.41M	5.43M	7.31M	4.00M
Total Liabilities	11.62M	25.38M	41.82M	84.56M	80.29M	70.26M
Stockholders Equity	115.13M	151.13M	212.08M	279.52M	288.42M	286.83M
Cash Flow
Free Cash Flow	-70.15M	-76.44M	-129.10M	-280.00K	-87.49M	-8.32M
Operating Cash Flow	-70.15M	-76.44M	-127.16M	322.00K	-85.80M	-6.08M
Investing Cash Flow	62.33M	49.47M	78.04M	-175.78M	-1.68M	-9.76M
Financing Cash Flow	110.00K	542.00K	842.00K	880.00K	95.56M	247.84M

Repare Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPTX, the sentiment is Positive. The current price of 2.12 is above the 20-day moving average (MA) of 1.97, above the 50-day MA of 1.88, and above the 200-day MA of 1.51, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 63.54 is Neutral, neither overbought nor oversold. The STOCH value of 36.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RPTX.

Repare Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	53 Neutral	$76.47M	-0.69	-49.78%	―	-82.16%	14.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LTRN	45 Neutral	$39.26M	―	-104.58%	―	―	1.18%
GBIO	39 Underperform	$35.36M	-0.48	-80.81%	―	-17.82%	57.32%
PLRX	37 Underperform	$98.83M	-0.47	-64.27%	―	―	14.19%
PRLD	35 Underperform	$99.61M	-0.99	-103.99%	―	250.00%	15.15%
UNCY	28 Underperform	$118.63M	―	-102.47%	―	―	66.05%

Repare Therapeutics Corporate Events

Repare Therapeutics Announces Acquisition by XenoTherapeutics

Repare Therapeutics Inc. has entered into an Arrangement Agreement with XenoTherapeutics, Inc., wherein Xeno’s subsidiary will acquire all outstanding common shares of Repare. Shareholders will receive a cash payment per share and a contingent value right for potential future payments. The transaction, deemed fair and in the best interest of the company by its board, requires shareholder and court approvals and is subject to customary closing conditions.

The most recent analyst rating on (RPTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.

Repare Therapeutics to be Acquired by XenoTherapeutics in Strategic Move

Repare Therapeutics has announced a definitive agreement to be acquired by XenoTherapeutics, Inc., a non-profit biotechnology company. Under the terms of the agreement, Repare shareholders will receive a cash payment estimated at $1.82 per share plus a contingent value right for potential future earnings. The transaction, expected to close in the first quarter of 2026, is part of Repare’s strategic efforts to maximize shareholder value through monetization of its portfolio and partnerships. This acquisition is seen as beneficial for stakeholders, providing immediate financial returns and opportunities for future gains through milestones and royalties.

The most recent analyst rating on (RPTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.

Repare Therapeutics’ Promising Study on Advanced Solid Tumors: A Closer Look

Repare Therapeutics Inc. is conducting a Phase 1/1b clinical study titled ‘Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors.’ The study aims to evaluate the safety, tolerability, and preliminary anti-tumor activity of RP-6306, both as a single agent and in combination with RP-3500 or Debio 0123, in patients with advanced solid tumors. The significance of this study lies in its potential to identify new treatment options for these patients.

Repare Therapeutics Unveils Phase 1 LIONS Trial Data

On October 22, 2025, Repare Therapeutics announced the availability of an abstract related to their Phase 1 LIONS trial of RP-1664. This preliminary data, showcasing the safety and antitumor activity of RP-1664 in advanced solid tumors, will be presented at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

The most recent analyst rating on (RPTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.